Form 4: Quest Diagnostics Officer's Stock Award & Tax Sale

Quest Diagnostics SVP & Chief Commercial Officer Mark E. Delaney received a performance stock award and subsequently sold shares to cover tax obligations.

Summary

• Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics Inc. (DGX), reported transactions involving the company's common stock.
• On March 4, 2026, Delaney acquired 5,682 shares of common stock at a price of $204.86 per share, which was a settlement of a performance stock award.
• Concurrently, on March 4, 2026, Delaney disposed of 2,326 shares of common stock at $204.86 per share, solely to cover tax withholding obligations arising from the performance stock award settlement.
• Following these reported transactions, Delaney beneficially owns 11,864 shares of Quest Diagnostics common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction related to executive compensation. The acquisition of shares via a performance award is a positive indicator of management's performance, offset by the standard tax-related sale, resulting in a slightly positive sentiment.

Positives

• The acquisition of 5,682 shares by a senior officer indicates the settlement of a performance stock award, suggesting the achievement of performance metrics by management.
• The officer's continued beneficial ownership of 11,864 shares aligns their interests with long-term shareholder value.

Negatives

• The disposition of 2,326 shares, even if for tax purposes, reduces the officer's direct holdings in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to performance-based compensation and tax withholding, are common occurrences in publicly traded companies. These transactions typically reflect pre-arranged compensation plans rather than discretionary trading based on new material information, and are standard practice across the healthcare diagnostics industry.

Stakeholder Impact

• Shareholders: The transactions are routine and reflect standard executive compensation practices. The officer's continued holding of shares aligns their interests with long-term shareholder value, which is generally viewed positively.

Key Dates

Keywords

Quest Diagnostics, DGX, Form 4, insider transaction, stock award, performance shares, executive compensation, Mark E. Delaney, common stock